Soluble interleukin-2 receptor levels in hepatocellular cancer: A more sensitive marker than alfa fetoprotein

Annals of Surgical Oncology

Volumn 6, Issue 2, 1999, Pages 178-185

  Izzo, Francesco ^a   Cremona, Francesco ^b   Delrio, Paolo ^b   Leonardi, Enrico ^b   Castello, Giuseppe ^b   Pignata, Sandro ^b   Daniele, Bruno ^b   Curley, Steven A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hepatitis virus; Hepatocellular cancer; Interleukin 2 receptor

Indexed keywords

ALPHA FETOPROTEIN; INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SCREENING; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; EARLY CANCER; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; RECURRENT CANCER;

EID: 0032958169     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0178-1     Document Type: Article

References (39)

1. Beasley R. HBV: the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
2. Di Bisceglie A. Hepatocellular carcinoma: molecular biology of its growth and relationship to HBV infection. Med Clin North Am 1989;73:985-97.
3. Arya S, Ashraf S, Parande C, et al. Hepatitis B and delta markers in primary hepatocellular carcinoma patients in the Gizan area of Saudi Arabia. Acta Pathol Microbiol Immunol Scand Suppl 1988; 3:30-4.
4. Bridbord K. Pathogenesis and prevention of hepatocellular carcinoma. Cancer Detect Prev 1989;14:191-2.
5. Di Bisceglie A, Rustgi V, Hoofnagle J, et al. NIH conference on hepatocellular carcinoma. Ann Intern Med 1988;108:390-401.
6. Rustgi V. Epidemiology of hepatocellular cancer. Gastroenterol Clin North Am 1987;16:545-51.
7. Anonymous. Hepatocellular cancer: differences between high and low incidence regions. Lancet 1987;2:1183-4.
8. Beasley RP, Hwang LY. Epidemiology of hepatocellular carcinoma. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. Orlando, FL: Grune and Stratton, 1984:209.
9. Esteban J, Gonzalez A, Hernandez J, et al. Evaluation of antibodies to HCV in a study of transfusion-associated hepatitis. N Engl J Med 1990;323:1107-12.
10. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive α-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996;111: 996-1001.
11. Yamazaki H, Oi H, Matsumoto K, et al. Biphasic changes in serum hepatocyte growth factor after transarterial chemoembolization therapy for hepatocellular carcinoma. Cytokine 1996;8:178-82.
12. Izzo F, Curley S, Maio P, et al. Correlation of soluble interleukin-2 receptor levels with severity of chronic HCV liver injury and development of hepatocellular cancer. Surgery 1996;120:100-5.
13. Bianchi L, DeGroote J, Desmet VJ, et al. Acute and chronic hepatitis revisited: classification of chronic hepatitis. Lancet 1997; 2:914-9.
14. Curley SA, Levin B, Rich TA. Liver and bile ducts. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical oncology. New York: Churchill Livingstone. 1995:1305-72.
15. Shapiro CN, Margolis HS. Hepatitis B epidemiology and prevention. Epidemiol Rev 1990;12:221-7.
16. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-55.
17. Alter JH. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 1993;2:155-66.
18. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
19. Unoura M, Kaneko S, Matsushita E, et al. High-risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology 1993;40:305-10.
20. Baron RL. Detection of liver neoplasms: techniques and outcomes. Abdom Imaging 1994;19:320-4.
21. The Liver Cancer Study Group of Japan. Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. Ann Surg 1990;211:277-87.
22. Choi TK, Lai ECS CS, Fan ST, et al. Results of surgical resection for hepatocellular carcinoma. Hepatogastroenterology 1990;37: 172-5.
23. Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery 1989;106:740-8.
24. Paquet K-J, Koussouris P, Mercado MA, et al. Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg 1991; 78:459-62.
25. Tsuzuki T, Sugioka A, Ueda M. Hepatic resection for hepatocellular carcinoma. Surgery 1990;107:511-20.
26. Kobayashi K, Sugimoto T, Makino H, et al. Screening methods for early detection of hepatocellular carcinoma. Hepatology 1985;5: 1100-5.
27. Sell S. Detection of cancer by tumor markers in the blood: a view to the future. Crit Rev Oncogenesis 1993;4:419-33.
28. Cottone M, Turri M, Caltagirone M, et al. Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alpha fetoprotein: a prospective study. Hepatogastroenterology 1989;35:101-3.
29. Okuda H, Obata H, Nakanishi T, et al. Production of abnormal prothrombin (des-γ-carboxy-prothrombin) by hepatocellular carcinoma: a clinical and experimental study. J Hepatol 1987;4:357-63.
30. Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Cancer 1994;73: 2464-71.
31. Kasahara A, Hayashi N, Fusamoto H, et al. Clinical evaluation of plasma des-gamma-carboxy-prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci 1993;38:2170-6.
32. Liaw YF, Tai DI, Chen TJ, et al. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis in hepatocellular carcinoma. Liver 1986;6:133-7.
33. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients. Cancer 1989;64: 1700-7.
34. Golondi L, Benzi G, Santi V, et al. Relationship between α-fetoprotein serum levels, tumour volume and growth rate of hepatocellular carcinoma in a Western population. Ital J Gastroenterol 1990;22:190-4.
35. Thung SN, Gerber MA, Sarno E, Popper H. Distribution of five antigens in hepatocellular carcinoma. Lab Invest 1979;41:101-5.
36. Diamantstein T, Osawa H, Mouzaki A, Josimovic-Alasevic O. Regulation of interleukin-2 receptor expression and receptor release. MoI Immunol 1986;23:1165-72.
37. Yamaguchi S, Onji M, Ohta Y. Increased serum soluble interleukin 2 receptor levels in patients with viral liver disease. Hepatogastroenterology 1988;35:245-8.
38. Muller C, Knoflach P, Zielinski CC. Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver disease. Hepatology 1989; 10:928-32.
39. Chu CM, Liaw YF. Serum levels of soluble TAC peptide in acute and chronic hepatitis B virus infection. Clin Immunol Immunopathol 1989;53:52-8.